ReviewChemistry (Weinheim an der Bergstrasse, Germany)2025
Strategy-Level Prodrug Synthesis.
Review in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Highly Reactive Oxygen Species (hROS) for Prodrug Activation through a Cascade Reaction with Kinetic Tunability (CReKT) to Effect Linker Cleavage.Journal of medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Organic synthesis uniquely provides opportunities to access molecules that serve defined purposes. Medicinal chemistry illustrates this attribute well with prodrug design, whereby a drug undergoes a late-stage conversion to a conditionally responsive active medicinal agent (AMA), being a notable example. Prodrugs are becoming increasingly important in medicinal chemistry but common approaches to introduce biologically responsive groups are limited in the chemoselectivity and scope of available functionalization reactions. This Concept article describes strategy-level prodrug synthesis, which is a powerful extension of classical prodrug formation that initiates sequences with the objective of introducing functionality early in a sequence to achieve greater scope, site-selectivity, and chemoselectivity for the incorporation of the biologically responsive group. Examples of functionalization using alkyne hydroamination, Curtius reaction, and alkene metathesis are highlighted along with the use of the prodrugs for biological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.